Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
DAWNRAYS PHARMA Subsidiary Obtains Drug Production Registration Approval for Trelagliptin Succinate Tablets
Recommend 3 Positive 5 Negative 0 |
||||
|
||||
|
DAWNRAYS PHARMA (02348.HK) announced that the Group’s subsidiary, Suzhou Dawnrays Pharmaceutical Co., Ltd., being the second of the PRC entities, has obtained the approval for drug production and registration for Trelagliptin Succinate Tablets 50mg and 100mg from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. This product is an oral hypoglycemic preparation for one week and can be used as monotherapy to improve blood sugar control in audit patients with type 2 diabetes. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
